Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSC | P53634 | 2/20 | 0.40 |
| ▸ | SLC15A2 | Q16348 | 1/20 | 0.40 |
| ▸ | REN | P00797 | 3/20 | 0.39 |
| ▸ | MMP1 | P03956 | 2/20 | 0.38 |
| ▸ | FCER2 | P06734 | 2/20 | 0.38 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.38 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.38 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.38 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.38 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.38 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.38 |
| ▸ | QRFPR | Q96P65 | 1/20 | 0.38 |
| ▸ | KDM1A | O60341 | 1/20 | 0.38 |
| ▸ | MAOA | P21397 | 1/20 | 0.38 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.37 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.37 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.37 |
| ▸ | CTSL | P07711 | 1/20 | 0.37 |
| ▸ | CTSB | P07858 | 1/20 | 0.37 |
| ▸ | CTSS | P25774 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2244570 | 0.98 | CTSC (0.40) | CTSCSLC15A2RENMMP1FCER2 | |
| SCHEMBL30692732 | 0.91 | MME (0.46) | SLC15A2ITGB3ITGA2B | |
| SCHEMBL5598794 | 0.91 | MME (0.46) | SLC15A2ITGB3ITGA2B | |
| SCHEMBL5598789 | 0.91 | MME (0.46) | SLC15A2ITGB3ITGA2B | |
| SCHEMBL4589435 | 0.90 | MME (0.45) | SLC15A2ITGB3ITGA2B | |
| SCHEMBL2244563 | 0.90 | MME (0.45) | SLC15A2ITGB3ITGA2B | |
| SCHEMBL4587279 | 0.88 | CTRB1 (0.44) | RENHDAC3HDAC4HDAC1HDAC2 | |
| SCHEMBL4588256 | 0.87 | SLC15A2 (0.36) | CTSCSLC15A2 | |
| SCHEMBL2241981 | 0.86 | CTRB1 (0.44) | RENHDAC3HDAC4HDAC1HDAC2 | |
| SCHEMBL25626461 | 0.85 | ACE (0.48) | QRFPRPTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080255032-A1 | METHODS AND COMPOSITIONS FOR PREVENTING AND TREATING AGING OR PHOTODAMAGED SKIN | PROCYTE CORPORATION (US) | 2008-10-16 | — | — | US | disclosed |
| US-7384916-B2 | Methods and compositions for preventing and treating aging or photodamaged skin | PROCYTE CORPORATION (US) | 2008-06-10 | — | — | US | disclosed |
| US-20060246029-A1 | Methods and compositions for preventing and treating aging or photodamaged skin | PROCYTE CORPORATION (US) | 2006-11-02 | — | — | US | disclosed |
| US-20060018851-A1 | Methods and compositions for preventing and treating hyperpigmentation of skin | PROCYTE CORPORATION (US) | 2006-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060246029-A1 | Methods and compositions for preventing and treating aging or photodamaged skin | RBP1, RBP4, SOD1 | CTSC 411/4885SLC15A2 2656/4885REN 1018/4885 |
| US-20060018851-A1 | Methods and compositions for preventing and treating hyperpigmentation of skin | RBP1, RBP4, MC1R | CTSC 752/4885SLC15A2 1582/4885REN 630/4885 |
| US-20080255032-A1 | METHODS AND COMPOSITIONS FOR PREVENTING AND TREATING AGING OR PHOTODAMAGED SKIN | RBP1, RBP4, SOD1 | CTSC 411/4885SLC15A2 2656/4885REN 1018/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.